Perspective Therapeutics Stock Forecast
NYSE: CATXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 2.46 +0.20%
CATX analyst consensus
Consensus (16 analysts)
strong_buy
Avg. price target
$12.29+399.59%
- Strong buy 2
- Buy 13
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 16 Wall Street analysts covering Perspective Therapeutics (2026-10-08), 15 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $12.29, with a high estimate of $18.00 and a low estimate of $5.00. The average target implies upside of 399.6% from the current price of $2.46.
The spread between the highest and lowest targets is 260.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CATX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 13% |
| Buy | 13 | 81% |
| Hold | 1 | 6% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $5.00 | +103.25% |
| Average target | $12.29 | +399.59% |
| High target | $18.00 | +631.71% |